Tenofovir for the treatment of breakthrough hepatitis caused by lamivudine and adefovir dipivoxil-resistant mutants of hepatitis B virus
Phase 4
- Conditions
- chronic hepatitis B
- Registration Number
- JPRN-C000000395
- Lead Sponsor
- Gunma Liver Study Group (GLSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Allergy to Lamivudine complication of chronic hepatitis coadministration of cytotoxic drugs leucopenia during pregnancy severe liver dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HBV-DNA
- Secondary Outcome Measures
Name Time Method serum ALT side effects